Arcellx (ACLX) Other Gross PP&E Adjustments (2021 - 2025)
Arcellx's quarterly Other Gross PP&E Adjustments came in at $23.4 million in Q4 2025, down 2.58% year-on-year from $24.0 million in Q4 2024, and up 200.64% quarter-over-quarter from -$23.2 million in Q3 2025.
Arcellx has reported Other Gross PP&E Adjustments for 5 years, with the latest figure at $23.4 million in Q4 2025.
- For the quarter ending Q4 2025, Other Gross PP&E Adjustments fell 2.58% year-over-year to $23.4 million; the trailing twelve-month figure through Dec 2025 stood at $23.4 million (down 2.58% YoY), and the FY2025 full-year result was $23.4 million, down 2.58% from the prior year.
- Other Gross PP&E Adjustments for Q4 2025 stood at $23.4 million, up from -$23.2 million in the prior quarter.
- The five-year high for Other Gross PP&E Adjustments was $24.0 million in Q4 2024, with the low at -$29.6 million in Q1 2023.
- Average Other Gross PP&E Adjustments over 5 years is -$13.8 million, with a median of -$23.6 million recorded in 2025.
- Peak annual rise in Other Gross PP&E Adjustments reached 178.4% in 2023, while the deepest fall reached 826.41% in 2023.
- Tracing ACLX's Other Gross PP&E Adjustments over 5 years: stood at $12.5 million in 2021, then sank by 266.42% to -$20.8 million in 2022, then soared by 178.4% to $16.3 million in 2023, then soared by 47.37% to $24.0 million in 2024, then retreated by 2.58% to $23.4 million in 2025.
- The last three Other Gross PP&E Adjustments figures came in at $23.4 million (Q4 2025), -$23.2 million (Q3 2025), and -$23.4 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 23.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 23.37 Mn |
| Dec 31, 2025 | 23.37 Mn |
| Sep 30, 2025 | -23.23 Mn |
| Sep 30, 2025 | -23.23 Mn |
| Jun 30, 2025 | -23.42 Mn |
| Jun 30, 2025 | -23.42 Mn |
| Mar 31, 2025 | -23.60 Mn |
| Mar 31, 2025 | -23.60 Mn |
| Dec 31, 2024 | 23.99 Mn |
| Dec 31, 2024 | 23.99 Mn |
| Sep 30, 2024 | -23.93 Mn |
| Sep 30, 2024 | -23.93 Mn |
| Jun 30, 2024 | -24.07 Mn |
| Jun 30, 2024 | -24.07 Mn |
| Mar 31, 2024 | -24.20 Mn |
| Mar 31, 2024 | -24.20 Mn |
| Dec 31, 2023 | 16.28 Mn |
| Dec 31, 2023 | 16.28 Mn |
| Sep 30, 2023 | -29.14 Mn |
| Sep 30, 2023 | -29.14 Mn |
| Jun 30, 2023 | -29.39 Mn |
| Jun 30, 2023 | -29.39 Mn |
| Mar 31, 2023 | -29.65 Mn |
| Mar 31, 2023 | -29.65 Mn |
| Dec 31, 2022 | -20.77 Mn |
| Dec 31, 2022 | -20.77 Mn |
| Sep 30, 2022 | -28.97 Mn |
| Sep 30, 2022 | -28.97 Mn |
| Jun 30, 2022 | -27.45 Mn |
| Jun 30, 2022 | -27.45 Mn |
| Mar 31, 2022 | -3.20 Mn |
| Mar 31, 2022 | -3.20 Mn |
| Dec 31, 2021 | 12.48 Mn |
| Dec 31, 2021 | 12.48 Mn |